The US Food and Drug Administration had permitted the use of the Pfizer-BioNTech COVID-19 Immunization in kids aged 5 to 11 for immunity against the Coronavirus.

The results were based on the FDA’s comprehensive and systematic examination of the data, which included participation from an expert advisory committee that strongly supported providing immunization to children in this age group.

It’s Hard To Monitor Racial Inequality In Children’s Immunizations.

The Pfizer-BioNTech COVID-19 Vaccine was developed in a two-dose primary sequence, three weeks’ intervals, for children aged 5 to 11, although at a smaller concentration (10 mcg) than that given to people aged 12 and up (30 mcg).

It's Hard To Monitor Racial Inequality In Children's Immunizations.

In the United States, COVID-19 infections in kids aged 5 to 11 account for 39% of all infections in those under the age of 18. And according to the Centers for Disease Control and Prevention (CDC), roughly 8,300 COVID-19 occurrences in children between the ages 5 to 11 years culminated in-hospital treatment. 

As of October 17, 691 COVID-19-related mortalities in people under the age of 18 had been confirmed in the United States, with 146 fatalities among children aged 5 to 11.

Vaccination is amongst the most cost-effective intervention strategies for preventing a wide range of infections in children and improving their overall wellbeing. Despite this, there is a significant gap in childhood vaccination coverage due to racial disparities.

The White House has made health equality a primary goal, and the nation’s coronavirus workgroup announced last week that the racial and social gap among entirely vaccinated individuals has been addressed. 

The Biden administration recently announced that it will invest roughly $800 million to support initiatives working to increase immunization trust among minorities and minimal income Citizens.

However, according to Dr. Georges Benjamin, executive director of the American Public Health Association, government, state, and municipal institutions for monitoring community statistical data are still insufficient and poorly funded, particularly information on racial inequities in child immunizations.

White kids were inoculated at substantially higher proportions than Black children in Michigan, Connecticut, and Washington, White kids between the ages of 13 and 17 in New York, on the other hand, are inoculated at reduced rates than Black, Hispanic, and Asian adolescents.

In Washington, the Black community at large continuing mistrust has been reflected in poor vaccination coverage amongst Black teenagers. 

According to the latest information from the District of Columbia Department of Health, the percentage of complete inoculation amongst Minority kids aged 12 to 15 is little over half that of white adolescents: 29 percent vs 54 percent. 

Despite weeks of public advocacy in the country’s capital, the Health Director of the department Dr. LaQuandra Nesbitt stated that hesitation has so far been hard to combat during a recent event to encourage the initiation of vaccines for kids as young as age 5.

Ultimately, the COVID-19 crisis has taught us that kids from historically disadvantaged racial/ethnic groups are not immune to the inequities that have wreaked havoc on adult people of color. 

We threaten to sustain the gap that exists for generation after generation if future programs do not promote equity above equality by allocating the resources based on its relative necessities assuring that kids from communities particularly impacted by COVID-19 are given preferential treatment.